ZA201602380B - Cancer treatment with combination of plinabulin and taxane - Google Patents
Cancer treatment with combination of plinabulin and taxaneInfo
- Publication number
- ZA201602380B ZA201602380B ZA2016/02380A ZA201602380A ZA201602380B ZA 201602380 B ZA201602380 B ZA 201602380B ZA 2016/02380 A ZA2016/02380 A ZA 2016/02380A ZA 201602380 A ZA201602380 A ZA 201602380A ZA 201602380 B ZA201602380 B ZA 201602380B
- Authority
- ZA
- South Africa
- Prior art keywords
- plinabulin
- taxane
- combination
- cancer treatment
- cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 229940123237 Taxane Drugs 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- UNRCMCRRFYFGFX-TYPNBTCFSA-N plinabulin Chemical compound N1C=NC(\C=C/2C(NC(=C\C=3C=CC=CC=3)/C(=O)N\2)=O)=C1C(C)(C)C UNRCMCRRFYFGFX-TYPNBTCFSA-N 0.000 title 1
- 229950011498 plinabulin Drugs 0.000 title 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2013/085075 WO2015051543A1 (en) | 2013-10-11 | 2013-10-11 | Cancer treatment with combination of plinabulin and taxane |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201602380B true ZA201602380B (en) | 2022-05-25 |
Family
ID=52812462
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2016/02380A ZA201602380B (en) | 2013-10-11 | 2016-04-08 | Cancer treatment with combination of plinabulin and taxane |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US10596169B2 (OSRAM) |
| EP (1) | EP3076972B1 (OSRAM) |
| JP (1) | JP6411523B2 (OSRAM) |
| KR (1) | KR102225371B1 (OSRAM) |
| CN (1) | CN105705148B (OSRAM) |
| AU (1) | AU2013402794B2 (OSRAM) |
| BR (1) | BR112016007946A2 (OSRAM) |
| CA (1) | CA2926771C (OSRAM) |
| DK (1) | DK3076972T3 (OSRAM) |
| ES (1) | ES2902665T3 (OSRAM) |
| IL (1) | IL244984B (OSRAM) |
| MX (1) | MX384751B (OSRAM) |
| MY (1) | MY185650A (OSRAM) |
| NZ (1) | NZ719049A (OSRAM) |
| RU (1) | RU2662298C2 (OSRAM) |
| SG (1) | SG11201602637QA (OSRAM) |
| WO (1) | WO2015051543A1 (OSRAM) |
| ZA (1) | ZA201602380B (OSRAM) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201706281YA (en) * | 2015-02-12 | 2017-09-28 | Beyondspring Pharmaceuticals Inc | Use of plinabulin in combination with immune checkpoint inhibitors |
| CN107530340B (zh) | 2015-03-06 | 2021-06-08 | 大连万春布林医药有限公司 | 治疗脑肿瘤的方法 |
| JP6769982B2 (ja) | 2015-03-06 | 2020-10-14 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | Ｒａｓ変異と関連するがんの治療方法 |
| WO2017011399A1 (en) | 2015-07-13 | 2017-01-19 | Beyondspring Pharmaceuticals, Inc | Plinabulin compositions |
| SG11201806583XA (en) | 2016-02-08 | 2018-09-27 | Beyondspring Pharmaceuticals Inc | Compositions containing tucaresol or its analogs |
| JP7025416B2 (ja) * | 2016-06-06 | 2022-02-24 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | 好中球減少症を低減させるための組成物および方法 |
| JP2020503363A (ja) | 2017-01-06 | 2020-01-30 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | チューブリン結合化合物およびその治療的使用 |
| MX2019009020A (es) * | 2017-02-01 | 2019-11-12 | Beyondspring Pharmaceuticals Inc | Metodo para reducir la neutropenia. |
| BR112019018880A2 (pt) * | 2017-03-13 | 2020-04-14 | Beyondspring Pharmaceuticals Inc | composições de plinabulina e seu uso |
| CN109498627B (zh) * | 2017-09-15 | 2021-06-04 | 深圳华大海洋科技有限公司 | 一种治疗肿瘤的药物组合物及其应用 |
| JP7350015B2 (ja) * | 2018-01-24 | 2023-09-25 | ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド | プリナブリンの投与による血小板減少症を軽減するための組成物および方法 |
| BR112020015758A2 (pt) * | 2018-02-01 | 2020-12-08 | Beyondspring Pharmaceuticals, Inc. | Composição e método para reduzir neutropenia induzida por quimioterapia através da administração de plinabulina e agente de g-csf |
| CN108524442B (zh) * | 2018-06-05 | 2022-01-28 | 深圳海王医药科技研究院有限公司 | 一种抗肿瘤药物的注射剂及其制备方法 |
| JP2018199726A (ja) * | 2018-09-26 | 2018-12-20 | ビヨンドスプリング インコーポレイテッド | プリナブリン及びタキサンの組合せがん治療 |
| CA3119768A1 (en) * | 2018-11-14 | 2020-05-22 | Beyondspring Pharmaceuticals, Inc. | Methods of treating cancer using tubulin binding agents |
| CN110507653B (zh) * | 2019-08-02 | 2022-12-02 | 北京赛而生物药业有限公司 | 多潘立酮及其与紫杉醇联用在制备治疗癌症的药物中的应用 |
| US20240299377A1 (en) * | 2019-10-15 | 2024-09-12 | Beyondspring Pharmaceuticals, Inc. | Methods and compositions for treating iron disorders |
| EP4319751A4 (en) * | 2021-04-09 | 2025-02-26 | Beyondspring Pharmaceuticals, Inc. | THERAPEUTIC COMPOSITIONS AND METHODS FOR THE TREATING OF TUMORS |
| CN113456643B (zh) * | 2021-08-11 | 2022-04-01 | 遵义医科大学 | 一种含普那布林的药物组合及其应用 |
| CN117860672A (zh) | 2022-10-11 | 2024-04-12 | 大连万春布林医药有限公司 | 一种普那布林胶束组合物及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7141603B2 (en) | 1999-02-19 | 2006-11-28 | The Regents Of The University California | Antitumor agents |
| US7012100B1 (en) | 2002-06-04 | 2006-03-14 | Avolix Pharmaceuticals, Inc. | Cell migration inhibiting compositions and methods and compositions for treating cancer |
| US7919497B2 (en) | 2002-08-02 | 2011-04-05 | Nereus Pharmaceuticals, Inc. | Analogs of dehydrophenylahistins and their therapeutic use |
| IL166628A0 (en) | 2002-08-02 | 2006-01-15 | Nereus Pharmaceuticals Inc | Dehydrophenyl lahistins and analogs thereof and the synthesis of dehydrophenyllahistins and analogs thereof |
| KR101228104B1 (ko) * | 2004-02-04 | 2013-02-01 | 니리어스 파마슈티컬즈, 인코퍼레이션 | 데하이드로페닐아히스틴 및 그의 동족체, 및 이들의합성방법 |
| GB0907551D0 (en) * | 2009-05-01 | 2009-06-10 | Univ Dundee | Treatment or prophylaxis of proliferative conditions |
| EP2968536B1 (en) | 2013-03-13 | 2023-06-28 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Methods for modulating chemotherapeutic cytotoxicity |
-
2013
- 2013-10-11 MX MX2016004441A patent/MX384751B/es unknown
- 2013-10-11 RU RU2016112608A patent/RU2662298C2/ru active
- 2013-10-11 BR BR112016007946A patent/BR112016007946A2/pt not_active Application Discontinuation
- 2013-10-11 CN CN201380080185.5A patent/CN105705148B/zh active Active
- 2013-10-11 CA CA2926771A patent/CA2926771C/en active Active
- 2013-10-11 DK DK13895342.7T patent/DK3076972T3/da active
- 2013-10-11 JP JP2016547208A patent/JP6411523B2/ja active Active
- 2013-10-11 AU AU2013402794A patent/AU2013402794B2/en active Active
- 2013-10-11 ES ES13895342T patent/ES2902665T3/es active Active
- 2013-10-11 US US15/028,376 patent/US10596169B2/en active Active
- 2013-10-11 MY MYPI2016000620A patent/MY185650A/en unknown
- 2013-10-11 EP EP13895342.7A patent/EP3076972B1/en active Active
- 2013-10-11 KR KR1020167012255A patent/KR102225371B1/ko active Active
- 2013-10-11 WO PCT/CN2013/085075 patent/WO2015051543A1/en not_active Ceased
- 2013-10-11 NZ NZ719049A patent/NZ719049A/en unknown
- 2013-10-11 SG SG11201602637QA patent/SG11201602637QA/en unknown
-
2016
- 2016-04-07 IL IL244984A patent/IL244984B/en unknown
- 2016-04-08 ZA ZA2016/02380A patent/ZA201602380B/en unknown
-
2020
- 2020-03-17 US US16/821,348 patent/US20200281921A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MY185650A (en) | 2021-05-27 |
| EP3076972B1 (en) | 2021-10-06 |
| KR102225371B1 (ko) | 2021-03-10 |
| AU2013402794B2 (en) | 2020-02-27 |
| CA2926771C (en) | 2022-07-05 |
| EP3076972A4 (en) | 2017-12-20 |
| US10596169B2 (en) | 2020-03-24 |
| NZ719049A (en) | 2020-06-26 |
| SG11201602637QA (en) | 2016-05-30 |
| BR112016007946A2 (pt) | 2017-09-12 |
| MX384751B (es) | 2025-03-14 |
| JP6411523B2 (ja) | 2018-10-24 |
| IL244984B (en) | 2022-05-01 |
| RU2016112608A (ru) | 2017-11-16 |
| DK3076972T3 (da) | 2022-01-03 |
| WO2015051543A1 (en) | 2015-04-16 |
| WO2015051543A8 (en) | 2016-04-21 |
| MX2016004441A (es) | 2016-10-28 |
| US20160250209A1 (en) | 2016-09-01 |
| EP3076972A1 (en) | 2016-10-12 |
| ES2902665T3 (es) | 2022-03-29 |
| AU2013402794A1 (en) | 2016-05-12 |
| US20200281921A1 (en) | 2020-09-10 |
| KR20160078987A (ko) | 2016-07-05 |
| CN105705148A (zh) | 2016-06-22 |
| JP2016536352A (ja) | 2016-11-24 |
| CN105705148B (zh) | 2021-03-23 |
| CA2926771A1 (en) | 2015-04-16 |
| IL244984A0 (en) | 2016-05-31 |
| RU2662298C2 (ru) | 2018-07-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201602380B (en) | Cancer treatment with combination of plinabulin and taxane | |
| IL273090B (en) | Methods and preparations for the treatment of cancer | |
| GB201320723D0 (en) | Composition and methods of treatment | |
| IL242386B (en) | Use of Aribolin and Lavetinib as a combination therapy for cancer treatment | |
| IL243215A0 (en) | Treatment of brain cancer with oncolytic adenoviruses | |
| SG10201801965RA (en) | Treatment of cancer with dihydropyrazino-pyrazines | |
| ZA201507733B (en) | Treatment of cancer with dihydropyrazino-pyrazines | |
| PL3060211T3 (pl) | Leczenie nowotworu i łagodnych chorób proliferacyjnych | |
| IL238481A0 (en) | Cancer treatment using synthetic lethal approaches | |
| IL242533B (en) | Naltrexone cancer treatment | |
| PL2948137T3 (pl) | Sposoby leczenia zwłóknienia i nowotworów | |
| GB201607581D0 (en) | Treatment of cancer | |
| SG10201802995SA (en) | Cancer treatment with combination of plinabulin and taxane | |
| GB201317373D0 (en) | Treatment and prevention of cancer | |
| GB201301685D0 (en) | Diagnosis and treatment of cancer | |
| GB201322346D0 (en) | Combination treatment of cancer | |
| TWI561255B (en) | Use of umirolimus and its derivatives for treating cancer | |
| GB201322958D0 (en) | Uses of oligouronates in cancer treatment | |
| GB201322347D0 (en) | Treatment of cancer | |
| GB201318742D0 (en) | Treatment of cancer | |
| GB201308529D0 (en) | Treatment of cancer | |
| GB201305020D0 (en) | Treatment of cancer | |
| GB201303115D0 (en) | Detection and treatment of liver cancer |